CD8A and neoplasm: In that regard, there was a difference between CD8+ T cells and Th1 cells, once again indicative of a switch from a “potential” tumor-reactive microenvironment (co-occurring with some immune suppressive factors), to an immune resistant phenotype in the MAPKi treatment resistant patients.